?

Diabetes Market Research Reports & Industry Analysis

The notion “diabetes” refers to a disease impacting the body’s ability to produce/use insulin. At present, more than 365 million people suffer from the disease worldwide. By 2030, the figure may reach 550 million. Inappropriate eating habits combined with a sedentary lifestyle, growth of the diabetic population and an increase in the number of obesity cases are amid the main factors contributing to the diabetes market growth. The list of the products available on the market is extensive: continuous blood glucose meters, anti-diabetic drugs, insulin and insulin pumps, artificial pancreas devices, etc.

Evaluated at over USD 19.8 billion, North America represents the top market, while Europe acts as the second largest player. The global diabetes market is expected to be at approximately USD 100 billion in 2018, showing a twofold increase if compared to 2011.

The Catalogue includes research reports dedicated to the diabetes market. The studies describe past and current industry trends, disclose data on the market competition and profile top industry behemoths. Information on the upcoming market events, industry growth drivers and hindrances can be found in the reports, too. Besides, the research reports contain evaluation of the actual economic situation, analyses of the market prospects.

Found 178 publications
FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (US) US$ 4,995.00

What environmental market barriers are influencing the Type 2 Diabetes (T2DM) market? From price to availability to reimbursement factors, FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (US) provides insights that can help develop, shape and refine your brand strategies. Also Available is FirstView Barriers – An Analysis of Market Barriers ...

Apr, 2015
FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (EU5) US$ 4,995.00

What market barriers are influencing the Type 2 Diabetes (T2DM) market? From price to availability to reimbursement factors, FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (EU5) provides insights that can help develop, shape and refine your brand strategies. Also Available is FirstView Barriers – An Analysis ...

Apr, 2015
PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 US$ 10,995.00

PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 SUMMARY Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the ... associated metabolic syndrome, treatment for brittle diabetes, and increased patient compliance. SCOPE Overview of type 1 diabetes, including epidemiology, etiology, pathophysiology, symptoms, diagnosis ...

Mar, 2015 289 pages
Physician Views: What Commercial Impact for Eylea from the Protocol T Study in Diabetic Macular Oedema? US$ 695.00

... 's Eylea). Converting any clinical advantage to the commercial setting may prove challenging, however, ... injection for Eylea. To better ascertain the impact of the Protocol T study results on uptake of Eylea, ... treatment of DME? In the first-line setting, what level of overall switching (or alternative new start ...

Apr, 2015
Diabetes Insipidus-API Insights, 2015 US$ 1,250.00

... Diabetes Insipidus. API intelligence over marketed drugs for Diabetes Insipidus and gaining primary intelligence over active ingredients manufacturers across the globe. Uncovering opportunities in the rapidly growing the US markets ...

Apr, 2015 60 pages
Physician Views: How do endocrinologists value diabetes-focused medical affairs teams – what could they be doing better? US$ 695.00

... and value of these teams. FirstWord's latest Physician Views poll seeks to gain some insight into how endocrinologists value the role that medical affairs ... asking US and EU5-based physicians: How important they view medical affairs teams in enabling effective communication between physicians and pharmaceutical companies? Which activities ...

Dec, 2014
Market Understanding for Diabetes Management Programs US$ 980.00

... of the Diabetes Educator 5. Take- aways from the Key Opinion Leaders (KOL’s) Takeaways: KOL’s 6. Growth Drivers & Barriers Diabetes Management: Drivers & Barriers Diabetes Management: Key Success Factors 7. Role of Technology in Diabetes Management Diabetes Management: Need Gap for new drugs & technology Diabetes Management: New Oral Agents Diabetes Management: Current Technology Diabetes Management ...

Nov, 2014 54 pages
Global Type 2 Diabetes Therapeutics Market 2015-2019 US$ 3,000.00 US$ 2,400.00

... diabetes, family history of diabetes, ethnicity, poor nutrition during pregnancy, unhealthy diet, physical inactivity, and IGT. TechNavio's analysts forecast the Global Type 2 Diabetes Therapeutics market ... , Japan, India, Russia, and other APAC countries) TechNavio's report, Global Type 2 Diabetes Therapeutics Market 2015-2019, has been prepared based on an in-depth market ...

Dec, 2014 112 pages
Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth US$ 4,995.00 US$ 4,496.00

... research, “Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth”, which provides insights into type 2 diabetes in the Asia-Pacific (APAC) markets ... trends in type 2 diabetes clinical trial size and duration in relation to industry averages Assess the potential risk of future developmental programs for type 2 diabetes therapeutics, depending ...

Nov, 2014 107 pages
Type 1 Diabetes (Juvenile Diabetes)-API Insights, 2015 US$ 1,250.00

... Type 1 Diabetes (Juvenile Diabetes). API intelligence over marketed drugs for Type 1 Diabetes (Juvenile Diabetes) and gaining primary intelligence over active ingredients manufacturers across the globe. Uncovering opportunities in the rapidly growing the US markets ...

Apr, 2015 60 pages
EpiCast Report: Type 1 Diabetes - Epidemiology Forecast to 2023 US$ 3,995.00 US$ 3,596.00

EpiCast Report: Type 1 Diabetes - Epidemiology Forecast to 2023 Summary Type 1 diabetes is a type of diabetes that accounts for 10% of all diabetes cases. The condition occurs as a result of the autoimmune destruction of pancreatic ... programs. Scope The Type 1 Diabetes EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for type 1 diabetes in the eight ...

Nov, 2014 49 pages
US Diabetes Monitoring, Treatment and Drug Delivery Market - 2014 US$ 6,995.00

... growing segments included the continuous glucose monitoring (CGM), insulin pump and supplies, modern insulin, insulin pens and pen needle markets. These segments have one aspect in common: they are newer ways of treating diabetes. CGM and pump technologies are improving at a fast pace toward full integration ...

May, 2014 212 pages
European Diabetes Monitoring, Treatment and Drug Delivery Market - 2013 US$ 10,995.00

This market includes traditional blood glucose meters, continuous glucose monitoring systems, blood glucose test strips, lancets and lancing devices, insulin, insulin syringes, insulin pens and insulin pumps. Market growth is expected to be fueled by an increasing number ...

Dec, 2012 229 pages
Diabetic Peripheral Neuropathy Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 US$ 2,000.00

SUMMARY DelveInsight’s, “ Diabetic Peripheral Neuropathy- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive ... the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. ...

Nov, 2014
Diabetic Neuropathy Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 US$ 2,000.00

SUMMARY DelveInsight’s, “ Diabetic Neuropathy- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights ... the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. ...

Nov, 2014
Diabetic Neuropathic Pain Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 US$ 2,000.00

SUMMARY DelveInsight’s, “ Diabetic Neuropathic Pain- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive ... (US DMF) available for Phase III Pipeline Drugs. Key discontinued Marketed products. Global Sales Figure from 2011-2015. Reasons to buy ...

Nov, 2014
Diabetic Nephropathy Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 US$ 2,000.00

SUMMARY DelveInsight’s, “ Diabetic Nephropathy- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights ... the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. ...

Nov, 2014
Diabetic Foot Infection (DFI) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 US$ 2,000.00

SUMMARY DelveInsight’s, “ Diabetic Foot Infection (DFI)- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish ...

Nov, 2014
Diabetes Insipidus Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 US$ 2,000.00

... SUMMARY DelveInsight’s, “ Diabetes Insipidus- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights ... (US DMF) available for Phase III Pipeline Drugs. Key discontinued Marketed products. Global Sales Figure from 2011-2015. Reasons to buy ...

Nov, 2014
Type 1 Diabetes (Juvenile Diabetes)- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 US$ 2,000.00

... and Asian Regions with location details. Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Type ... . Understanding the chemical route of synthesis of approved drugs for Type 1 Diabetes (Juvenile Diabetes). Uncovering opportunities in the rapidly growing the US markets ...

Nov, 2014
Physician Views: Five key diabetes market questions ahead of ADA 2014 US$ 695.00

... product to Lantus now known as Toujeo. See Physician Views Poll Results – Usage of Sanofi's U300 will not ... this point. In the oral diabetes market, there are two key trends to watch. In the GLP ... , FirstWord is polling US and EU5-based endocrinologists on five key questions ahead of the ADA meeting, Specifically ...

Apr, 2015
Global Diabetic Retinopathy Market 2015-2019 US$ 2,500.00

... scenario and the growth prospects of the global diabetic retinopathy market for the period 2015-2019. To calculate the market size, the report considers revenue from the ... the market at large, as well as the key trends that contribute to the growth the market. Technavio's report, Global Diabetic Retinopathy Market 2015-2019, has been prepared based on an in-depth market ...

May, 2015 84 pages
Type 2 Diabetes Global Clinical Trials Review, H1, 2014 US$ 2,500.00 US$ 2,250.00

... Type 2 Diabetes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Type 2 Diabetes. It includes an overview of the trial numbers and their recruitment ...

May, 2014 319 pages
Type 1 Diabetes (Juvenile Diabetes) Global Clinical Trials Review, H1, 2014 US$ 2,500.00 US$ 2,250.00

... clinical trial report, “Type 1 Diabetes (Juvenile Diabetes) Global Clinical Trials Review, H1, 2014' provides data on the Type 1 Diabetes (Juvenile Diabetes) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Type 1 Diabetes (Juvenile Diabetes ...

May, 2014 198 pages
Proliferative Diabetic Retinopathy (PDR) Global Clinical Trials Review, H1, 2014 US$ 2,500.00 US$ 2,250.00

... trial report, “Proliferative Diabetic Retinopathy (PDR) Global Clinical Trials Review, H1, 2014' provides data on the Proliferative Diabetic Retinopathy (PDR) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Proliferative Diabetic Retinopathy (PDR ...

May, 2014 106 pages
Diabetes Insipidus Global Clinical Trials Review, H1, 2014 US$ 2,500.00 US$ 2,250.00

Diabetes Insipidus Global Clinical Trials Review, H1, 2014 SUMMARY GlobalData's clinical trial report, “Diabetes Insipidus Global Clinical Trials Review, H1, 2014' provides data on the Diabetes Insipidus clinical trial ...

May, 2014 52 pages
Diabetic Ketoacidosis Global Clinical Trials Review, H1, 2014 US$ 2,500.00 US$ 2,250.00

Diabetic Ketoacidosis Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Diabetic Ketoacidosis Global Clinical Trials Review, H1, 2014' provides data on the Diabetic Ketoacidosis clinical trial ...

Apr, 2014 61 pages
Diabetic Foot Ulcers Global Clinical Trials Review, H1, 2014 US$ 2,500.00 US$ 2,250.00

Diabetic Foot Ulcers Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Diabetic Foot Ulcers Global Clinical Trials Review, H1, 2014' provides data on the Diabetic Foot Ulcers clinical trial ...

Apr, 2014 99 pages
PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update US$ 10,995.00 US$ 9,896.00

... will increase due to rapid economic growth. We anticipate that the type 2 diabetes market will not experience a fundamental shift in the classes of drugs ... recent therapeutic guidelines putting emphasis on a patient-tailored approach in treating type 2 diabetes, pharmaceutical companies will achieve considerable success with their me-too ...

Jan, 2014 465 pages
PharmaPoint: Microvascular Complications of Diabetes - Global Drug Forecast and Market Analysis to 2022 US$ 10,995.00 US$ 8,796.00

... Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet ... of microvascular complications of diabetes (which is attributed to the dramatic increase in prevalence of type 2 diabetes worldwide) and due to the uptake of one novel branded drug for diabetic nephropathy ...

Dec, 2013 367 pages
PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022 US$ 4,995.00 US$ 3,996.00

PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely ... therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing ...

Dec, 2013 150 pages
PharmaPoint: Microvascular Complications of Diabetes - UK Drug Forecast and Market Analysis to 2022 US$ 4,995.00 US$ 3,996.00

PharmaPoint: Microvascular Complications of Diabetes - UK Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely ... therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing ...

Dec, 2013 143 pages
PharmaPoint: Microvascular Complications of Diabetes - Spain Drug Forecast and Market Analysis to 2022 US$ 4,995.00 US$ 3,996.00

PharmaPoint: Microvascular Complications of Diabetes - Spain Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing ... of generic competitors. The uptake of drugs receiving additional approval for diabetic retinopathy/DME, such as Eylea, Iluvien and Ozurdex, will further ...

Dec, 2013 143 pages
PharmaPoint: Microvascular Complications of Diabetes - Japan Drug Forecast and Market Analysis to 2022 US$ 4,995.00 US$ 3,996.00

PharmaPoint: Microvascular Complications of Diabetes - Japan Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing ... therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing ...

Dec, 2013 145 pages
PharmaPoint: Microvascular Complications of Diabetes - Italy Drug Forecast and Market Analysis to 2022 US$ 4,995.00 US$ 3,996.00

PharmaPoint: Microvascular Complications of Diabetes - Italy Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing ... of generic competitors. The uptake of drugs receiving additional approval for diabetic retinopathy/DME, such as Eylea, Iluvien and Ozurdex, will further ...

Dec, 2013 144 pages
PharmaPoint: Microvascular Complications of Diabetes - Germany Drug Forecast and Market Analysis to 2022 US$ 4,995.00 US$ 3,996.00

PharmaPoint: Microvascular Complications of Diabetes - Germany Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing ... therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing ...

Dec, 2013 144 pages
PharmaPoint: Microvascular Complications of Diabetes - France Drug Forecast and Market Analysis to 2022 US$ 4,995.00 US$ 3,996.00

PharmaPoint: Microvascular Complications of Diabetes - France Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing ... therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing ...

Dec, 2013 145 pages
Ranirestat (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00 US$ 2,796.00

Ranirestat (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high ... number of generic competitors. Ranirestat is being developed jointly by Dainippon Sumitomo Pharma and Eisai for the treatment of diabetic neuropathy. The drug is currently ...

Dec, 2013 73 pages
PharmaPoint: Microvascular Complications of Diabetes - Current and Future Players US$ 2,995.00 US$ 2,396.00

PharmaPoint: Microvascular Complications of Diabetes - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Microvascular Complications of Diabetes - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Microvascular Complications of Diabetes ...

Dec, 2013 51 pages
Optina (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00 US$ 2,796.00

Optina (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high ... for the treatment of diabetic retinopathy and DME. Effective non-surgical drug treatment of diabetic retinopathy is a high unmet need and Optina is the only ...

Dec, 2013 74 pages
Lucentis (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00 US$ 2,796.00

Lucentis (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high ... other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. Lucentis (ranibizumab) is a humanized fragment ...

Dec, 2013 59 pages
Eylea (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00 US$ 2,796.00

Eylea (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high ... other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. Eylea is a fusion protein consisting ...

Dec, 2013 75 pages
Avastin (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00 US$ 2,796.00

Avastin (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high ... other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. Avastin (bevacizumab) is a recombinant humanized ...

Dec, 2013 58 pages
Atrasentan (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00 US$ 2,796.00

Atrasentan (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high ... number of generic competitors. Atrasentan hydrochloride is being developed by AbbVie and is currently in Phase III trials for the treatment of diabetic nephropathy. Atrasentan is a highly selective ...

Dec, 2013 74 pages
UAE Diabetes Market Opportunity Analysis 2018 US$ 600.00

... the local domestic production sector, but the major hurdle is that UAE is not well equipped and does not posses the required capability ... country is thus a net importer of devices used for diabetes care. “UAE Diabetes Market Opportunity Analysis 2018” gives comprehensive insight on following aspects related ...

Jan, 2014 33 pages
EpiCast Report: Diabetic Neuropathy - Epidemiology Forecast to 2022 US$ 3,995.00 US$ 3,196.00

EpiCast Report: Diabetic Neuropathy - Epidemiology Forecast to 2022 Summary Diabetic neuropathy affects an estimated 50% of patients with diabetes and is one of the leading causes of morbidity in diabetic patients, often leading to foot ... diagnosed prevalent cases of diabetes in the 7MM. Scope The diabetic neuropathy EpiCast Report provides an overview of the risk factors and epidemiological trends for diabetic neuropathy in the seven ...

Nov, 2013 45 pages
Tresiba (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00 US$ 2,796.00

Tresiba (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Tresiba (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type 2 diabetes ... Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Tresiba including ...

Jul, 2013 46 pages
Trelagliptin (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00 US$ 2,796.00

Trelagliptin (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Trelagliptin (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type 2 diabetes ... Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Trelagliptin including ...

Jul, 2013 60 pages
Tradjenta (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00 US$ 2,796.00

Tradjenta (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Tradjenta (Type 2 Diabetes) - Forecast and Market Analysis to 2022'. The type 2 diabetes ... Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Tradjenta including ...

Jul, 2013 47 pages
Tofogliflozin (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00 US$ 2,796.00

Tofogliflozin (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Tofogliflozin (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type 2 diabetes ... novel branded drugs. Tofogliflozin is an SGLT-2 inhibitor being investigated in Phase III clinical trials for the oral treatment of type 2 diabetes by Chugai Pharmaceutical. The ...

Jul, 2013 59 pages
1 2 3 4 >
Skip to top